ALSO NOTED: Roche gets OK to reintroduce Viracept in Europe; Japanese brewer may buy local drug maker;

> Roche can sell Viracept in the European Union again; regulators there reinstated the drug maker's license for the HIV remedy. Report

> Japanese brewer Kirin, faced with declining beer sales, wants to beef up its pharma business, possibly by acquiring midsize drug maker Kyowa Hakko. Report

> Indian drug maker Ranbaxy Laboratories posted skyrocketing profits for the third quarter--$50 million on sales of $406 million, some 48 percent higher than the same period last year. Much of the gain was due to the strong rupee, however; factoring out that effect, profits rose 13 percent. Report

> Sanofi Pasteur won FDA approval for its meningococcal vaccine, Menactra, for use in kids ages 2 through 10; it was already approved for those 11 through 55. Report

> In all the hoopla over the new FDA funding-and-reform legislation last month, a key provision was eclipsed--the creation of a new research center paid for by drug makers. Report

And Finally... A sweet idea: Scientists are advising surgeons to consider using honey to speed wound healing and reduce infection. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.